

July 10, 2013

**Press Release related to the initiation of Phase 2 clinical study on HP-3060
(a transdermal long-acting system for the treatment of allergic rhinitis)**

Hisamitsu Pharmaceutical (Head office: Tosu city, Saga Prefecture, Japan: President and CEO: Hiroataka Nakatomi) announced today that it initiated a Phase 2 clinical study on a transdermal long-acting system for the treatment of allergic rhinitis (development code: HP-3060), which is under development in Japan by Hisamitsu.

HP-3060 is a systemic tape formulation developed by utilizing Hisamitsu's TDDS (Transdermal Drug Delivery System) technology. We expect HP-3060 to be a new option for the treatment of allergic rhinitis by realizing its long-lasting effect by means of maintaining a stable blood concentration.

In the Phase 2 clinical study, the pharmacokinetics, efficacy, and safety will be studied by repeated-dose administration of HP-3060 or placebo in adults with allergic rhinitis.

Hisamitsu aims to initiate a Phase 3 study during FY2014.